Guidant BioTherapeutics is a clinical-stage oncology company advancing a differentiated pipeline of dual-cytokine immunotherapies and

next-generation dual-targeting dual-toxin antibody-drug conjugates (ADCs). This pipeline is built on a clinically-validated, proprietary, navigated tumor delivery platform designed to enhance efficacy while reducing systemic toxicity. The company’s lead clinical-ready asset, an IL-15/IL-12 dual-cytokine program, leverages over $120 million of prior investment that has already established the human safety profile, platform technology, intellectual property, and clinical supply, significantly

de-risking development. With clearly defined value-creation milestones expected over the next 2 years, Guidant is seeking $20–$40 million in growth capital to advance clinical execution, unlock platform partnerships, and create significant value inflection.